How to buy AbCellera Biologics stock

AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.

AbCellera Biologics share price

Use our graph to track the performance of ABCL stocks over time.

AbCellera Biologics shares at a glance

• Key figures

Information last updated 2021-03-09.

52-week range	$26.16 - $71.91
50-day moving average	$43.81
200-day moving average	$43.75
Wall St. target price	$55.80
PE ratio	3270.405
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.02

Buy AbCellera Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AbCellera Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of AbCellera Biologics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is AbCellera Biologics under- or over-valued?

Valuing AbCellera Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbCellera Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AbCellera Biologics's P/E ratio

AbCellera Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3270x. In other words, AbCellera Biologics shares trade at around 3270x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, AbCellera Biologics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• XBiotech (XBIT.US): 1.20

AbCellera Biologics financials

Revenue TTM	$28.4 million
Gross profit TTM	$1.5 million
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0.98%
Book value	N/A
Market capitalisation	$8.2 billion

TTM: trailing 12 months

Shorting AbCellera Biologics shares

There are currently 2.2 million AbCellera Biologics shares held short by investors – that's known as AbCellera Biologics's "short interest". This figure is 23.1% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting AbCellera Biologics shares can be evaluated.

AbCellera Biologics's "short interest ratio" (SIR)

AbCellera Biologics's "short interest ratio" (SIR) is the quantity of AbCellera Biologics shares currently shorted divided by the average quantity of AbCellera Biologics shares traded daily (recently around 671808.10810811). AbCellera Biologics's SIR currently stands at 3.33. In other words for every 100,000 AbCellera Biologics shares traded daily on the market, roughly 3330 shares are currently held short.

To gain some more context, you can compare AbCellera Biologics's short interest ratio against those of similar companies.

• Genmab A/S (GMAB.US): 0.7
• XBiotech (XBIT.US): 12.36
• Aridis Pharmaceuticals (ARDS.US): 0.46

However AbCellera Biologics's short interest can also be evaluated against the total number of AbCellera Biologics shares, or, against the total number of tradable AbCellera Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbCellera Biologics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AbCellera Biologics shares in existence, roughly 10 shares are currently held short) or 0.0186% of the tradable shares (for every 100,000 tradable AbCellera Biologics shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbCellera Biologics.

Find out more about how you can short AbCellera Biologics stock.

AbCellera Biologics share dividends

We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.

AbCellera Biologics overview

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Frequently asked questions

• How many people work for AbCellera Biologics?

  Latest data suggests 174 work at AbCellera Biologics.

• When does the fiscal year end for AbCellera Biologics?

  AbCellera Biologics's fiscal year ends in December.

• Where is AbCellera Biologics based?

  AbCellera Biologics's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1